INNOVATION FOR GOOD HEALTH INNOVATION FOR GOOD HEALTH
1
Care for Life Continuous Innovation Our pursuit of innovation never stops. From original invention to technical improvement, we enable lives to enjoy good health.
Pursuit of Excellence Win-Win Cooperation
CONTENTS
P2 Our Brand
P8 Our Vision
P12 Our Products & Services
P18 Our Teams
P22 Our Responsibility
Our Brand
01
We adhere to our brand concept “Innovation for Good Health”, care for life, continuous innovation, strive for excellence and win-win cooperation, we are the leading pharmaceutical and healthcare group in China.
Research and Development
Pharmaceutical Manufacturing
Healthcare Services
Pharmaceutical Distribution and Retail
Medical Diagnosis
Medical Devices
Company Profile Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196-SH, 02196-HK), established in 1994, is a leading company in China’s pharmaceutical and healthcare industry. Fosun Pharma strategically operates in several key sectors in the pharmaceutical and healthcare industry, including pharmaceutical manufacturing, distribution and retail, medical diagnosis and devices, and healthcare services, making contribution to public health. Fosun Pharma has a national-level technology center and an international R&D team, focusing on innovative R&D in therapeutic areas such as cardiovascular system, metabolism and alimentary tract, central nervous system, blood system, anti-tumor as well as anti-infective treatment. In future, Fosun Pharma will adhere to its brand concept of “Innovation for Good Health”, and insists on its business strategy of “organic growth with external expansion and integrated business operation”. We are dedicated to becoming a first class enterprise in major global healthcare market.
For more information, please visit
www.fosunpharma.com or follow us on WeChat (QR code):
INNOVATION FOR GOOD HEALTH
3
Board of Directors
4
Mr. Chen Qiyu
Mr. Yao Fang
Mr. Guo Guangchang
Mr. Wang Qunbin
Ms. Kang Lan
Executive Director Chairman
Executive Director Vice Chairman and CEO
Non-executive Director
Non-executive Director
Non-executive Director
Mr. Wang Pinliang
Mr. John Changzheng Ma
Mr. Zhang Weijiong
Mr. Cao Huimin
Mr. Jiang Xian
Mr. Wong Tin Yau Kelvin
Non-executive Director
Non-executive Director
Independent Nonexecutive Director
Independent Nonexecutive Director
Independent Nonexecutive Director
Independent Nonexecutive Director
INNOVATION FOR GOOD HEALTH
5
Brand Concept “Innovation for Good Health” —Our pursuit of innovation never stops. From original invention to technical improvement, we enable lives to enjoy good health.
Values
Care for Life
Continuous Innovation
We always care for human life, and endeavor to
We insist on independent R&D. Targeting at diseases that
improve the life quality of patients and their families.
endanger public health, we bring new possibilities for life
We cherish our living environment, and set green
and health via innovation breakthroughs.
and sustainable philosophy as guidelines for all
We create a a flexible and independent environment
business activities.
for scientific research, providing fertile ground for
We actively participate in and push forward actions
pharmaceutical innovation and technological improvement.
that benefit public health and environmental
We establish innovative management model and process,
improvement.
continuously improving the overall efficiency of corporate operation.
6
Pursuit of Excellence
Win-Win Cooperation
We put quality above everything else, establish
We practice diversified cooperation with
a production and management system with the
open-minded attitude, push forward business
highest international standards, and continuously
integration with common ideas, and promote
improve the manufacturing process, so as to
the synergy of industry values.
ensure quality and safety of our drugs.
We strive for the construction of a healthy
We continuously improve our capability of R&D
business eco-system, creating long-term values
and operation in pursuit of excellence.
for our employees, customers, shareholders and the society, so as to achieve sustainable development in the entire industry. INNOVATION FOR GOOD HEALTH
7
Our Vision
A first class enterprise in major global market
With global competitiveness
A leading enterprise to conduct internationalization in China
02 8
We are dedicated to becoming a first class enterprise in major global healthcare market
Combining China’s Growth Momentum with Global Resources Leverage its strength of well-established industry foundation, distribution network and investment experience, Fosun Pharma utilizes high quality capital, talents, brands and technologies around the globe to achieve all-round internationalization in products, markets, planning and operation, talents, capital and branding by following the business strategy of “organic growth with external expansion, integrated business operation”.
Europe United States China
Africa
To bring in high-caliber scientists team from developed countries such as the United States, and carry out R&D on generic drugs, biopharmaceutical drugs and innovative drugs in Shanghai, Chongqing, San Francisco and Taipei simultaneously To export the Artesunate series drugs in developing countries To market biosimilar drugs in China, and export chemical generic drugs and biopharmaceutical generic drugs to emerging and mature markets. To build on capabilities for the marketing of innovative drugs to global markets To establish the global presence and operational capability for medical devices To build up capability for integrating global healthcare resources
As of 30 June 2015, 13 APIs of Fosun Pharma received certifications from the
13
cGMP International Certification
U.S. FDA, EU Certification, Ministry of Health, Labour and Welfare of Japan, and Federal Ministry of Health of Germany. Guilin Pharma has 1 production line for oral solid dosage formulation, 4 production lines for injection and 2 production lines for APIs which obtained PreQualification from the World Health
APIs
Organization (WHO-PQ), as well as 11 formulation products listed in the WHOPQ catalog. Yao Pharma also has 1 production line of oral dosage formulation which obtained the GMP certification from the Canada FDA and the U.S. FDA, and passed site inspection.
INNOVATION FOR GOOD HEALTH
9
Research and Development Fosun Pharma R&D Center
Fosun Pharmaceutical Industry Research Institute
Clinical Research Center
Chemical Drugs Innovation R&D Center (Small molecular chemical drugs)
Biotech Drugs R&D Center (Monoclonal antibody agents drugs)
Generic Drugs R&D Center (Generic drugs with high entry barriers)
Specialized Formulations R&D Center (Sustained and controlled release technology)
Innovation Investment Platform
Medical Diagnosis and Devices R&D Center
4+1 Pharmaceutical R&D platform
“4+1” R&D platform Fosun Pharma always takes independent innovation as the driving force for our development, and improves our R&D system which combines generic and innovative drug development. Fosun Pharma established a unique“4+1” R&D platform focusing on small molecular innovative chemical drugs, large molecular biosimilars, generic drugs with high entry barriers and special formulation technology, and actively follows up the cutting-edge technology in global pharmaceutical industry.
5.64
4.38
R&D Investments and Achievements
unit: RMB100 million
2013
In 2014, the R&D expenditures of Fosun Pharma were RMB564 million, representing an increase of 28.93% year on year; while in the first half of 2015, the expenditures were RMB299 million, representing an increase of 17.75% year on year. Fosun Pharma, with other entities including WuXi PharmaTech, jointly invested in Ambrx Inc., a clinical trial R&D company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics. As of 30 June 2015, Fosun Pharma had 130 pipeline drugs, generic drugs, biosimilars and vaccine projects, 37 projects under clinical trial applications, 13 projects under clinical trial, and 33 projects awaiting official approval for sales.
2014
R&D expenditures
2.99 2.54
unit: RMB100 million
Strategic Alliances for Innovation and R&D Fosun Pharma’s Zhangjiang Innovation and R&D Park focuses on high-end pharmaceutical R&D, in particular the highly promising biotechnology drug, it also plans to build an integrated platform of new drug R&D and pilot test in the future. Fosun Pharma formed the “Fosun Pharma Technology Innovation Strategic Alliance” with prestigious research institutes in China, which is one of the “Industry-Academia-Research Strategic Alliances” initiatives under the national major projects for pharmaceutical innovation and manufacturing. In cooperation with Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Fosun Pharma established a new R&D model and develop three anti-tumor innovative drugs through riskand-benefit sharing scheme.
10
2014H1
2015H1
R&D expenditure in the first half of the year
R&D Team Fosun Pharma owns a national-level technical center and has established highly-efficient international R&D teams in Shanghai, Chongqing, San Francisco and Taipei. As of 30 June 2015, Fosun Pharma has 866 pharmaceutical R&D employees.
Shao Ying
Fu Jiemin
Vice President and Director of
Senior Adviser to President
R&D Center
and a national evaluation expert on new drugs
Deng Jie
Wang Weibo
Scott Liu
Liu Xuejun
Co-head of large molecular
Deputy Director of R&D Center
innovative chemical drugs team,
biosimilars team, a full
and Co-head of specialized
and a talent recruited through
participant in developing
formulations R&D team
the “One-Thousand Talents
Orencia for rheumatoid
Programme” by Organization
arthritis and Vectibix for colon
Department of the CPC Central
cancer
Co-head of generic drugs
Co-head of small molecular
with high entry barriers team
Committee
Lei Huangshu
Zhao Xingdong
Jiang Weidong
Co-head of generic drugs
Co-head of small molecular
Co-head of large molecular
with high entry barriers team
innovative chemical drugs
biosimilars team, led and
team
participated in the R&D of a number of antibody and protein drugs including Vitaxin and Rituxan Biobetter.
INNOVATION FOR GOOD HEALTH
11
Business Overview
03 12
We uphold to our “pursuit of excellence” attitude on products and services, continue to improve our healthcare service and management level through technology advancement, management optimization and service innovation, in order to provide safe, reliable and effective drugs to the public.
Pharmaceutical Manufacturing In 2014, Fosun Pharma’s pharmaceutical manufacturing and R&D segment recorded operating revenue of RMB7.337 billion, representing an increase of 11.43% year on year; while in the first half of 2015, the operating revenue was RMB4.121 billion, representing an increase of 21.58% year on year. In the first half of 2015, the sales of the Fosun Pharma’s major pharmaceutical products maintained rapid growth, among which, the sales of major products in the anti-tumor therapeutic area increased by 43.69% year on year, the sales of major products in the blood system therapeutic area increased by 29.29%, and the sales of major products in the cardiovascular system therapeutic area increased by 24.49% year on year. Rank in China’s major pharmaceutical companies according to IMS CHPA 2015 Q2
NO.4
Pharmaceutical manufacturing and R&D are the core component of Fosun Pharma's strategic development. According to IMS CHPA2015 Q2, Fosun Pharma ranked 4th among major pharmaceutical companies in China. In2014, Fosun Pharma has 17 formulation products and series with over RMB100 million sales, among which: the sales of Compound Aloe Capsules and Xihuang Capsules exceeded RMB100 million for the first time, and the sales of Ao De Jin and Atomolan exceeded RMB500 million.
73.37 65.84 41.21 33.89
Unit: RMB100 million
2013
2014
Operating revenue from pharmaceutical manufacturing and R&D segment
Unit: RMB100 million
2014H1
2015H1
Operating revenue from pharmaceutical manufacturing and R&D segment in the first half of 2015
INNOVATION FOR GOOD HEALTH
13
17
Products with sales over RMB100 million
Therapeutic Areas and Major Products Therapeutic areas
Metabolism and Alimentary Tract
Products Atomolan
Reduced glutathione for Injection / Tablets / Hepatoprotection
Wan Su Lin
Protamine Zinc Insulin Injection / Type II diabetes
Wan Su Ping
Glimepiride Tablets / Type II diabetes
Yi Bao
TCM / Stomach problems, chronic atrophic gastritis and gastrulae
You Li Tong
Hyperuricemia patients with metabolic arthritis symptoms
Xin Xian An
Central Nervous System
You dier
Meglumine Adenosine Cyclophosphate Injection / Coronary artery heart disease, cardiac failure, arrhythmia and sick sinus syndrome Alprostadil Dried Emulsion for Injection / Cardiovascular and cerebrovascular microcirculation, chronic hepatitis Low-molecular-weight Heparin Sodium for Injection / Inhibit coagulation during blood dialysis, and prevent deep vein thrombosis
Ao De Jin
Deproteinized Calf Blood Serum Injection / Improve blood circulation in the brain and neurological deficit caused by nutritional disease (ischemic injury and cranial trauma)
Bang Ting
ARTESUN-PLUS, ARTESUN
Anti-infective
Hyperactivity of heart-liver fire, constipation, abdominal distension & abdominal pain, and irritability & insomnia
Su Ke Nuo
Qi Wei
Blood System
Recombinant Human Erythropoietin for Injection / Anemia caused by renal insufficiency, including dialysis and non-dialysis patients
Mo Luo Dan Compound Aloe Capsules
Cardiovascular
Chemical names / indications
Quetiapine Fumarate Tablets / Negative and positive symptoms of schizophrenia
Hemo-coagulase for Injection / Haemostasis
Artesunate Preparation series / Various malarial diseases
Xi Chang
Cefmetazole Sodium for injection / microorganism-caused infections
Natrii Kalii
Potassium Sodium Pehydroandrographolide Succinate for Injection / viral pneumonia and viral upper respiratory tract infection
Yi Nuo Ni Kang
Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets II / for a 2-month initial phase intensive treatment of the short term therapy of tuberculosis
Rifampicin Capsules
Eluzer Anti-tumor
Xihuang Capsules
Rifampicin Capsules / tuberculosis & enterococcal infections
Pemetrexed Disodium for Injection/non-small cell lung cancer and malignant pleural mesothelioma Syndrome of toxicity and blood stasis acute, superficial infection, dorsal furuncle swelling, multiple abscess, adenolymphitis, cold abscess
14
Medical Diagnosis and Devices Alma Lasers operates businesses in over
60
countries and regions
Fosun Pharma begins its in-vitro diagnostic business fairly early in China with diversified scope. Our products cover clinical chemistry, clinical immunology, molecular diagnostics (including gene-chip technology and PCR), clinical microbiology etc. We are one of the independent R&D enterprises that produce large volume of in-vitro diagnostic products in China. Owns leading and reputable brands such as “Long March” and “Yaneng” Having invested in domestic and overseas industries, and established strategic cooperation in technology, products and markets Fosun Pharma operates its medical devices businesses mainly through Chindex Medical Limited (CML), with products covering core areas of surgery, aesthetics, imaging, oncology, dental, and transfusion-related devices. Da Vinci surgical robotic system, agented by CML, helps improve surgical operation level in China significantly Alma Lasers is a leading medical and aesthetic device manufacturer globally with businesses covering more than 60 countries and regions including the United States, Germany and Brazil, and has become the market leader of the high-end aesthetic devices. Up to now 5 products have received certification from EU Certification and 3 have received certification from the U.S. FDA Partnered with Foshan Chancheng Central Hospital to establish the laser plastic surgery center, which marks the full launch of the international strategy across Fosun Pharma’s medical and health industry chain
INNOVATION FOR GOOD HEALTH
15
In 2014, the operating revenue of Sinopharm was RMB
200.131
billion
Pharmaceutical Distribution and Retail Sinopharm(stock code: 01099. HK) In 2003, Fosun Pharma co-founded Sinopharm with CNPGC. Sinopharm is the largest pharmaceutical and healthcare products distributor, and leading supply chain service provider in China. It also owns the largest retail pharmacy chain in the country. Sinopharm was listed in Hong Kong in 2009. In 2014, Fosun Pharma and Sinopharm completed the integration of pharmaceutical distribution and retail business, including Fosun Pharmaceutical, Forme Pharmacy and Golden Elephant Pharmacy, so as to optimize resources allocation. Fosun Pharma currently holds 27.83% equity interest in Sinopharm and holds 4 out of the 9 board seats of non-independent directorships. Fosun Pharma benefits from Sinopharm’s extensive distribution network, good industry reputation and comprehensive supply-chain system, and leverages on the synergy with Sinopharm’s distribution network for driving the company’s business growth.
Partnered up with Guahao.com to build up new business model In 2015, Fosun Pharma and Guahao.com signed a strategic cooperation agreement. Both parties will make the best of their superior recourses to carry out in-depth collaboration, among which pharmaceutical e-commerce and medical services are the key areas for cooperation. Guahao.com is the largest Internet-based medical platform in China, coveing 1,420 hospitals, 150,000 experts, with over 82 million registered patients with real-name, the appointment requests for the year of 2015 reached 200 million people.
16
Beijing
United Family Hospital
Fosun Pharma has substantially completed its strategic deployment of healthcare services with high-end healthcare services in the moredeveloped coastal cities featuring "United Family" brand, and oncology specialty and general hospitals in second-tier and third-tier cities.
Tianjin
Suqian Hefei
Shanghai
Foshan Chancheng Hospital Yueyang
Zhongwu Hospital Guangji Hospital
Shenzhen Foshan
Jimin Cancer Hospital
Healthcare Services United Family Hospital, a high-end private hospital with the most popularity and the highest level of internationalization, is the first choice of medical treatment for foreign expatriates, and local wealthy and middle-class group. It has established hospitals and clinics in Beijing, Shanghai, Tianjin and Qingdao. Chancheng Hospital is a large-scale Tier III general hospital that has considerable influence in Foshan and the Pearl River Delta areas. Anhui Jimin Cancer Hospital is the first oncology specialty hospital in Anhui Province. Guangji Hospital in Yueyang, Hunan Province and Zhongwu Hospital in Suqian, Jiangsu Province are both tier II general hospitals and has high reputation in their respective regions. In the first half of 2015, Zhongwu Hospital has started the construction of a habilitation and body-check hospital, and the construction of the “Taizhou Zanyang Medical Care Project” was also launched.
INNOVATION FOR GOOD HEALTH
17
Operation and Management
04 18
We pursue the concept of openness and integration, and advocate for win-win cooperation. Fosun Pharma cooperates with outstanding domestic and foreign entrepreneur teams, working together to create values and share development progress. The entrepreneurial spirit of our team is one of the core competitiveness of Fosun Pharma.
Management Team Our management team has an average of more than 15 years of industry experience, with excellent track record and extensive expertise in the industry.
Mr. Yao Fang
Mr. Li Dongjiu
Mr. Wang Cheng
Mr. Li Chun
Mr. Hongfei Jia
Executive Director Vice Chairman and CEO
Senior Vice President Chairman of Pharmaceutical Commerce and Consumer Goods Management Committee
Senior Vice President Director of Pharmaceutical Industry Management Committee
Senior Vice President
Senior Vice President
Mr. Zhou Biao
Mr. Wu Yifang
Mr. Zhang Xinmin
Mr. Pu Qiangling
Ms. Guan Xiaohui
Senior Vice President Secretary of the Board of Directors and General Manager of the Regulatory Department
Senior Vice President Director of Pharmaceutical Industry Management Committee
Senior Vice President
Senior Vice President Chairman of Medical Device Department
Senior Vice President Chief Finance Officer
Mr. Song Jinsong
Mr. Cui Zhiping
Mr. Zhu Yaoyi
Mr. Wang Kexin
Mr. Bing Li
Senior Vice President Director of Medical Service Management Committee
Vice President
Vice President General Manager of Medical Diagnosis Division
Vice President
Vice President General Manager of the International Department
Mr. Dong Zhichao
Mr. Wang Yao
Mr. Shao Ying
Mr. Chen Yuqing
Ms. Mei Jingping
Vice President Director of R&D Center
Vice President General Manager of Human Resources Department
Vice President General Manager of Strategic Planning Department
Vice President Vice President General Manager of Zhangjiang Innovation General Manager of Medical Devices Division R&D Base
INNOVATION FOR GOOD HEALTH
19
In 2014, the operating revenue wasRMB
12.026
billion
Financial Performance Fosun Pharma proactively transforms itself to adapt to market changes, by implementing innovation strategy, optimizing organizational structure, as well as improving its management system, so as to prompt efficient operations in the company. In 2014, Fosun Pharma recorded operating revenue of RMB12.026 billion, and net profit attributable to shareholders of listed company of RMB2.113 billion, up by 20.30% and 33.51% year on year respectively; in the first half of 2015, Fosun Pharma recorded operating revenue of RMB5.921 billion, and net profit attributable to shareholders of listed company was RMB1.303 billion, up by 6.91% and 28.10% year on year respectively. Fosun Pharma strives to create value for the society and returns to shareholders with integrity. As of the end of 2014, the shareholder's equity increased by 3,111.95% compared to the listing year of 1998. The company has distributed dividends for 15 consecutive years. Fosun Pharma takes tax payable as a pride achievement, the total tax payable was RMB1.268 billion in 2014.
120.26
12.86
21.13 99.96 10.51 15.64
15.83
73.41
7.89
Unit: RMB 100 million
Unit: RMB 100 million
2012
2013
2012
2014
Operating revenue
55.39
2013
2014
Unit: RMB 100 million
2012
Net profit attributable to shareholders of the listed company
59.21 13.03 10.18
Unit: RMB 100 million
2014H1
2015H1
Operating revenue of the first half year
20
Unit: RMB 100 million
2014H1
2015H1
Net profit attributable to shareholders of the listed company in the first half year
2013
2014
Tax payable
Business Integration Case Study We have solid experience and proven track record in acquisition and business integration
Revenue increased by 672% since the merge and acquisition in 2002
672% 205,555 161,005 132,543
Ranks as top 3 in liver protection treatment area In 2002, acquired Yao Pharma, adjusted its development strategies and business philosophy, and established professional teams In 2005, acquired Carelife Pharma to be the raw material manufacturing platform In 2007, set up a Haisiman Pharma, strengthening the construction of marketing teams In 2009, Carelife Pharma and Kaixing Pharma became wholly subsidiaries In 2010, acquired the majority shares of Hexin Pharma, enriching combination of formulation products In 2013, established a joint venture JeilYao Pharma Co., Ltd
Unit: RMB 10,000
2012
2013
2014
Occupies a leading position in areas of endocrinology and metabolism in terms of Revenue increased by 1,029% since the merge and acquisition in 2004
1,029% 180,388 141,440 101,136
market size In 2004, acquired Wanbang Biopharma to conduct business integration, and guided its development In 2006, established Wanbang Jinqiao on the basis of raw material workshop In 2008, established Wanbang Marketing, which is responsible for the sales of Wanbang Pharma’s products In 2009, acquired controlling shares of Folon Pharma, Ltd. and Shanghai Chemo Biopharma to start group development In 2011, acquired the majority of shares of Zhaohui Pharma In 2013, acquired the majority of shares of Wanbang Sainuokang Biochemical In 2014, signed a strategic cooperation agreement with Huanghe Pharma
Unit: RMB 10,000
2012
2013
2014
Alma Lasers’ businesses vary from product R&D and manufacturing to end-user service field Updating laser technology from overseas to serve clients in China at the earliest time possible Successful practice of the concept of “Combining China's Growth Momentum with Global Resources” The full launch of the international strategy across Fosun Pharma’s medical and health industry chain The model, if successfully replicated in the future, will have considerable potential
INNOVATION FOR GOOD HEALTH
21
Our Responsibility
05 22
Fosun Pharma releases CSR report every year, reflecting the harmonious situation between corporation and society; we actively practice corporate social responsibility, and push forward the sustainable development of the whole industry with outstanding enterprises.
2013 2014
RMB1.9 RMB2.36
In 2014, the contribution to society per share increased by 19.49% over 2013.
19.49% Reward the society In 2014, the contribution to society per share was RMB2.36, up by 19.49% over 2013; we have provided more than 250 million artemisinin-based anti-malaria oral medicine globally; we helped over 100 million hepatopaths bring illness under control; we effectively improved health condition of approximately 10 million diabetics every year; since 2010, we have helped 2 million patients suffered from impaired mental functions and other diseases
Environmental health and safety
No.1 Industry rank of the CSR report
Since 2008, our investment for environmental protection construction and reconstruction reached over RMB110 million; In 2014, our water consumption per RMB10,000 decreased 10.76%; power consumption per RMB10,000 decreased 3.95%year on year; energy consumption per RMB10,000 decreased 15.12% year on year
“Future Star” Charity Program The public charity programs of Fosun Pharma is named as “Future Star”. Based on the foundation of the “Future Star” charity education program, Fosun Pharma hopes to perform its social responsibility and make contribution to the society through various channels by supporting education, funding research projects, providing medicine and healthcare community services, donations, disaster relief and so on. Since 2006, Fosun Pharma has undertaken nearly 100 projects on fighting against malaria in Africa in response to the call of the Chinese government. Fosun Pharma set up a volunteer team so as to encourage its employees to participate in social service and public charity undertakings. In 2014, Fosun Pharma donated more than RMB10 million (including materials and personal donations) to society.
Staff Development
In 2014, promotion rate of the company reached
11.48%
Fosun Pharma values the sustainable development of talents, putting forward the talent concept of “Attract talents by development, Unite people with business, Cultivate staff in working and Assess people according to performance”. Currently, the entrepreneurial spirit of our team is one of the core competitiveness of Fosun Pharma. In 2014, the promotion rate of Fosun Pharma reached 11.48%; the total number of employees reached 18,081, up by 7.6% over 2013. Meanwhile, Fosun Pharma continually improves its salary and welfare system. All employees of the group have payment higher than the local minimum wage. In 2014, Fosun Pharma’s cash payment to and on behalf of the employees totaled RMB1.632 billion, an increase of 30.97% from 2013.
INNOVATION FOR GOOD HEALTH
23
Corporate Culture Fosun Pharma always puts a close connection of personal development (Self-improvement), takes good care of social relationship and environment (Teamwork), corporate success (Performance) with contribution to society and country (Contribution to Society).
Fosun Pharma values multicultural integration and overall achievements of the team. We respect diverse background of different enterprises, and emphasize open-minded communication is the key for establishing mutual trust and support, cooperation and unity that fully demonstrate the functions of teamwork.
24
Honors and Awards Industry Status No. 4 “2014 China Pharmaceutical Industry Top 100 Enterprises”
NO.4 No. 1 Evaluation Report of Environmental Responsibility Information Disclosure of Chinese Listed Companies
NO.1
Fosun Pharma ranked No. 16 in the “2014 Top 100 Enterprises of Pharmaceutical Industry in China announced” (by the Ministry of Industry and Information Technology of the PRC) No. 14 in the "Top 100 Enterprises of Pharmaceutical Manufacturing Industry in China for 2014" (by Southern Medicine Economic Institute under China Food and Drug Administration) No. 4 in the “2014 China Pharmaceutical Industry Top 100 Enterprises” (by China Pharmaceutical Industry Association) Admitted to the SSE 180 Index, CSI 300 Index, and the SSE Dividends Index, the SSE Corporate Governance Index, the SSE Private Enterprises Index, the SSE Social Responsibility Index and CCTV Finance 50 Index
Evaluation of CSR In 2014, the Company’s 2013 corporate social responsibility report was rated “annual AA+” by the Rankins CSR Ratings (ranked the third in 665 A-share listed companies altogether), ranked No. 1 in pharmaceuticals industry. (by Rankin’s CSR Ratings) In 2014, in the Evaluation Report of Environmental Responsibility Information Disclosure of Chinese Listed Companies released by Lowcarbon Economics Research Center of Beijing University of Chemical Technology, Fosun Pharma ranked No.1 among all companies participated in the assessment. Awarded the “Best Public Welfare Practice” by the third 2014 China Charity Festival (by Shaanxi TV, China.com(Finance), Huanqiu.com, Gongyi.baidu.com) Awarded the Best CSR 2014 by the China Finance Summit (by more than 30 financial and public media including China.com, Chinanews.com, and Takungpao.com ) Awarded“2013 GoldenBee Corporate Social Responsibility Report • Outstanding Growth Enterprises” (“WTO Guide”, only three enterprises had this honor)
Top 20 “The Most Competitive Listed Pharmaceutical Enterprises”
20
Top
Market Assessment Elected as one of the “Top 50 Enterprises with Integrity Listed on the Main Board of China” (by Association of Chinese Economic Press and IPO123.cn) Elected as one of “The Top 20 Most Competitive Listed Pharmaceutical Enterprises” (by Chinese Pharmaceutical Enterprises Association, Healthcare Executive Magazine and Hejun Consulting) Elected as one of the first “China’s Next Global Giants Top 100 by ACCA” (by the Association of Chartered Certified Accountants) Awarded as the “Best Board of Directors of the Gold Round Table Award” for five consecutive years from 2010-2014 (by “Gold Round Table ” Forum for Boards of Chinese Listed Companies) Awarded the Award of Best Business Model on the Sixth Xin Cai Fu Award Ceremony of “Business Models with the Most Growth Potential” organized by Xin Cai Fu Magazine (by Xin Cai Fu Magazine)
INNOVATION FOR GOOD HEALTH
25
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233 Tel: +86 21 3398 7000 Fax: +86 21 33987020 Postcode: 200233
●
Designed by Brand & Public Relations Department of Fosun Pharmaceutical (Group) Co., Ltd.
Follow us on WeChat
Data updated from 2015 Interim Report